Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15765305 | 0.90 | DRD2 (0.52) | DRD2SIGMAR1 | |
| SCHEMBL27246689 | 0.81 | TDP1 (0.52) | DRD2TDP1SIGMAR1TPSAB1TPSD1 | |
| SCHEMBL30945709 | 0.81 | DRD2 (0.48) | DRD2TDP1MAOAMAOB | |
| SCHEMBL22291518 | 0.79 | TPSAB1 (0.54) | DRD2TDP1TPSAB1TPSD1TPSG1 | |
| SCHEMBL9773851 | 0.79 | TPSAB1 (0.54) | DRD2TDP1TPSAB1TPSD1TPSG1 | |
| SCHEMBL31655700 | 0.79 | TPSAB1 (0.54) | DRD2TDP1TPSAB1TPSD1TPSG1 | |
| SCHEMBL31637593 | 0.78 | DRD2 (0.46) | DRD2TDP1SIGMAR1MAOAMAOB | |
| SCHEMBL3387585 | 0.78 | DRD2 (0.47) | DRD2TDP1SIGMAR1 | |
| SCHEMBL8139824 | 0.77 | BRD4 (0.53) | DRD2TDP1TPSAB1TPSD1TPSG1 | |
| SCHEMBL8103180 | 0.77 | DRD2 (0.57) | DRD2TDP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838696-B1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2016-03-09 | — | — | EP | disclosed |
| US-8053446-B2 | Cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2011-11-08 | — | — | US | disclosed |
| US-20080312275-A1 | Novel Cyanoguanidine Compounds | LEO PHARMA A/S (DK) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312275-A1 | Novel Cyanoguanidine Compounds | MKI67, CCNA1, COL1A1 | DRD2 2257/4885TDP1 291/4885SIGMAR1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.